• Contact/
  • Home/

  • About
  • Team
  • Portfolio
  • Exit History
  • News

  • About
  • Team
  • Portfolio
  • Exit History
  • News

  • Advent Life Sciences
  • Advent Life Sciences

Page 6 of 24

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10Next >End >>
05.01.2021Aura Biosciences Appoints David Johnson to Its Board of Directors

Press Release

22.10.2020F2G Receives Second US FDA Breakthrough Therapy Designation for Olorofim

Press Release

13.10.2020Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs

Press Release

02.09.2020Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis

Press Release

12.08.2020PIC Therapeutics Appoints Dr. Katherine Bowdish as Chief Executive Officer

Press Release

12.08.2020F2G Closes US$60.8 Million Financing to fund late stage development of novel mechanism antifungal agent

Press Release

11.08.2020Advent Life Sciences announces sale of its portfolio Company KaNDy Therapeutics to Bayer AG for USD 425M upfront plus USD 450M in potential development milestones followed by further potential commercial milestones.

Press Release

06.08.2020Acutus Medical Announces Pricing of Initial Public Offering

Press Release

17.07.2020Zikani Therapeutics Appoints Chief Scientific and Medical Officer

Press Release

24.06.2020Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158

Press Release



  • Privacy Policy
  • Legal and Regulatory Matters

©2022 Advent Life Sciences